Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 581

Results For "SSI"

5896 News Found

Lupin receives U.S. FDA approval for HIV-1 drug
Pharma | June 08, 2021

Lupin receives U.S. FDA approval for HIV-1 drug

Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021


Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr
News | June 05, 2021

Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr

The company is doubling its chemistry research capacity that should commission by Q2'FY22


Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Govt. to procure 30 Cr COVID-19 vaccine doses from Biological-E
News | June 03, 2021

Govt. to procure 30 Cr COVID-19 vaccine doses from Biological-E

These vaccine doses will be manufactured and stockpiled by the company from August-December 2021


Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application
News | June 03, 2021

Lupin announces U.S. FDA acceptance for pegfilgrastim biosimilar application

Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).


Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
News | June 03, 2021

Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India

Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC


Haffkine Biopharma to produce 22.8 Cr doses of Covaxin
News | June 03, 2021

Haffkine Biopharma to produce 22.8 Cr doses of Covaxin

For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Remdesivir demand was exaggerated: Dr. Sharvil Patel
News | May 28, 2021

Remdesivir demand was exaggerated: Dr. Sharvil Patel

Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines